Business
Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
MARLBOROUGH, Mass., Oct. 26, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"MARLBOROUGH, Mass., Oct. 26, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced three upcoming poster presentations discussing INTASYL compounds, including posters being delivered by two development partners, AgonOx, Inc. and the Helmholtz Zentrum München, at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020.\nPhoto - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg \nPoster details are as follows:\nPoster Sponsor: \nPhio Pharmaceuticals \nTitle:\nCombination intratumoral treatment with INTASYL™ self-delivering RNAi targeting TIGIT and PD-1/PD-L1 improves tumor control compared to monotherapy in a CT26 model of murine colorectal cancer\nAuthors: \nBenjamin Cuiffo, et al.\nAbstract Number:\n198\nPoster Sponsor:\nAgonOx, Inc. \nTitle:\nIncreasing activation of human tumor-reactive T cells (CD39+CD103+CD8+) bygene silencing of PD1 with self-delivering RNAi INTASYLTM\nAuthors:\nColin J. Thalhofer, et al.\nAbstract Number:\n172\nPoster Sponsor: \nHelmholtz Zentrum München\nTitle: \nNew checkpoints controlling function of cytotoxic lymphocytes infiltrating human carcinoma\nAuthors: \nAnna Herbstritt, et al.\nAbstract Number:\n599\nAn archived version of the Phio presentation will be made available on the \"Investors – Events and Presentations\" section of the Company's website (click here).\nAbout Phio Pharmaceuticals Corp.\nPhio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com.\nForward Looking State...